Hansoh Pharmaceutical Group Company Limited
HNSPF
$5.20
$0.4910.40%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 19.60% | 22.06% | 23.10% | 12.61% | 2.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.60% | 22.06% | 23.10% | 12.61% | 2.18% |
| Cost of Revenue | 6.29% | 5.93% | 4.36% | 8.37% | 13.04% |
| Gross Profit | 21.12% | 23.94% | 25.32% | 13.08% | 1.07% |
| SG&A Expenses | 4.70% | 2.77% | -0.45% | -1.66% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -41.44% | 185.31% | 826.78% | 144.08% | -25.62% |
| Total Operating Expenses | 10.89% | 9.79% | 7.30% | 5.71% | 4.08% |
| Operating Income | 43.83% | 57.01% | 69.26% | 31.60% | -2.75% |
| Income Before Tax | 33.31% | 53.21% | 76.30% | 48.18% | 20.59% |
| Income Tax Expenses | 43.96% | 58.95% | 76.86% | 51.23% | 26.06% |
| Earnings from Continuing Operations | 31.72% | 52.38% | 76.22% | 47.75% | 19.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.72% | 52.38% | 76.22% | 47.75% | 19.82% |
| EBIT | 43.83% | 57.01% | 69.26% | 31.60% | -2.75% |
| EBITDA | 39.58% | 50.80% | 60.87% | 28.13% | -2.28% |
| EPS Basic | 31.75% | 52.22% | 76.04% | 47.41% | 19.51% |
| Normalized Basic EPS | 33.15% | 50.89% | 70.43% | 43.25% | 16.60% |
| EPS Diluted | 39.53% | 53.63% | 68.05% | 39.87% | 12.29% |
| Normalized Diluted EPS | 35.41% | 51.20% | 68.63% | 41.42% | 14.74% |
| Average Basic Shares Outstanding | 0.09% | 0.10% | 0.11% | 0.13% | 0.15% |
| Average Diluted Shares Outstanding | -1.16% | 0.08% | 1.34% | 1.43% | 1.52% |
| Dividend Per Share | 61.40% | 103.72% | 172.50% | 144.14% | 107.63% |
| Payout Ratio | 1.18% | 0.21% | -0.50% | -0.40% | -0.26% |